Venatorx Pharmaceuticals Inc., of Malvern, Pa., said the FDA granted the company's lead antibiotic program, VNRX-5133, an injectable broad-spectrum beta-lactamase inhibitor combined with a marketed beta-lactam antibiotic, qualified infectious disease product and fast track designations for both complicated urinary tract infections and complicated intra-abdominal infections.